These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34614211)

  • 1. The cure of leukemia through the optimist's prism.
    Kantarjian HM; Jain N; Garcia-Manero G; Welch MA; Ravandi F; Wierda WG; Jabbour EJ
    Cancer; 2022 Jan; 128(2):240-259. PubMed ID: 34614211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
    Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
    Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
    Assi R; Kantarjian H; Short NJ; Daver N; Takahashi K; Garcia-Manero G; DiNardo C; Burger J; Cortes J; Jain N; Wierda W; Chamoun S; Konopleva M; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):897-901. PubMed ID: 28927784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
    Jabbour E; Haddad FG; Short NJ; Kantarjian H
    JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias.
    Zou JY; Huang SM; Zhoub HX; Xu MZ; Sun AN; Wu DP; Xue SL; Zhang TT
    Hematology; 2023 Dec; 28(1):2237790. PubMed ID: 37477259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
    Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
    Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline treatment of acute myeloid leukemia in adults.
    Tamamyan G; Kadia T; Ravandi F; Borthakur G; Cortes J; Jabbour E; Daver N; Ohanian M; Kantarjian H; Konopleva M
    Crit Rev Oncol Hematol; 2017 Feb; 110():20-34. PubMed ID: 28109402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
    Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
    J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
    Borthakur G; Cortes JE; Estey EE; Jabbour E; Faderl S; O'Brien S; Garcia-Manero G; Kadia TM; Wang X; Patel K; Luthra R; Koller C; Brandt M; Ravandi F; Kantarjian H
    Am J Hematol; 2014 Oct; 89(10):964-8. PubMed ID: 24990142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.